Neuroprotection and Neuroregeneration of the Injured Spinal Cord: A Focus on Degenerative Cervical Myelopathy - Commentary on "Pharmacological Treatment of Degenerative Cervical Myelopathy: A Critical Review of Current Evidence".

The sodium-glutamate antagonist riluzole, based on a Phase 3 multicenter randomized controlled trial (RCT), failed to achieve significance in enhancing the modified Japanese Orthopaedic Association (mJOA) score, largely because of ceiling effects in the outcome measure, but did show signal in a number of secondary outcomes including neck and arm pain.

also in 299 other papers